Literature DB >> 31649860

Cleaning up the environment in juvenile myelomonocytic leukemia.

Lisa Deng1,2, Rebecca J Chan1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 31649860      PMCID： PMC6812558          DOI： 10.21037/tcr.2017.02.06

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  9 in total

Review 1.  Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.

Authors:  Adam P Curnock; Marisa K Logan; Stephen G Ward
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

2.  Molecular basis of juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; C Michael Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

3.  Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria.

Authors:  Eva Bergstraesser; Henrik Hasle; Tim Rogge; Alexandra Fischer; Martin Zimmermann; Peter Noellke; Charlotte M Niemeyer
Journal:  Pediatr Blood Cancer       Date:  2007-10-15       Impact factor: 3.167

4.  Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation.

Authors:  Shen Y Heazlewood; Rebecca J Neaves; Brenda Williams; David N Haylock; Timothy E Adams; Susan K Nilsson
Journal:  Stem Cell Res       Date:  2013-05-28       Impact factor: 2.020

5.  Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.

Authors:  Lei Dong; Wen-Mei Yu; Hong Zheng; Mignon L Loh; Silvia T Bunting; Melinda Pauly; Gang Huang; Muxiang Zhou; Hal E Broxmeyer; David T Scadden; Cheng-Kui Qu
Journal:  Nature       Date:  2016-10-26       Impact factor: 49.962

6.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

Authors:  Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

7.  Risk assessment in chronic myelomonocytic leukemia (CMML).

Authors:  U Germing; A Kündgen; N Gattermann
Journal:  Leuk Lymphoma       Date:  2004-07

8.  Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Authors:  Kimberly A Hartwell; Peter G Miller; Siddhartha Mukherjee; Alissa R Kahn; Alison L Stewart; David J Logan; Joseph M Negri; Mildred Duvet; Marcus Järås; Rishi Puram; Vlado Dancik; Fatima Al-Shahrour; Thomas Kindler; Zuzana Tothova; Shrikanta Chattopadhyay; Thomas Hasaka; Rajiv Narayan; Mingji Dai; Christina Huang; Sebastian Shterental; Lisa P Chu; J Erika Haydu; Jae Hung Shieh; David P Steensma; Benito Munoz; Joshua A Bittker; Alykhan F Shamji; Paul A Clemons; Nicola J Tolliday; Anne E Carpenter; D Gary Gilliland; Andrew M Stern; Malcolm A S Moore; David T Scadden; Stuart L Schreiber; Benjamin L Ebert; Todd R Golub
Journal:  Nat Chem Biol       Date:  2013-10-27       Impact factor: 15.040

9.  Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.

Authors:  Dan Xu; Xia Liu; Wen-Mei Yu; Howard J Meyerson; Caiying Guo; Stanton L Gerson; Cheng-Kui Qu
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.